Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MediWound's $70m IPO at low end of target

This article was originally published in Clinica

Executive Summary

Israel’s MediWound has priced its initial public offering, but the $70m total was at the low end of its expectations. The firm had been hoping to sell five million shares at $14-16 each, raising up to $80m in total, in fact had to settle for the bottom of this range. The underwriters also have the option to purchase up to 750,000 more shares at the same price, which could top up the grand total. The company began trading on the Nasdaq today under the ticker symbol MDWD. In spite of the disappointing total, the offering will be heartening to both MediWound and other start-ups considering taking a chance on the public market. So far this year, Clinica has recorded a total of 12 filings, and four, including MediWound, have succeeded in going public, bolstering hopes that the medtech IPO market is picking up.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel